Bluejay Diagnostics: A Battle Against Time and Capital

While Bluejay Diagnostics continues to make tangible progress in the clinical development of its sepsis diagnostic technology, its shares are experiencing a severe downturn. The company is now embroiled in a critical race against time, facing a potential cash exhaustion as early as next year that threatens to overshadow its scientific achievements.

The company’s clinical endeavors are moving forward. The SYMON-II study has successfully enrolled half of its target patient population. The development timeline projects the Symphony IL-6 test to enter its testing phase by 2026, potentially leading to FDA approval in 2027. However, these forward-looking plans are clouded by a stark financial reality. Bluejay Diagnostics has officially expressed substantial doubt about Read more...